Last reviewed · How we verify
Tocilizumab Prefilled Syringe
At a glance
| Generic name | Tocilizumab Prefilled Syringe |
|---|---|
| Also known as | Actemra, RoActemra |
| Sponsor | Syneos Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation (PHASE2)
- Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers (PHASE1)
- An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy (PHASE3)
- Cri Analog PG1 Effectiveness and Safety in Covid-19 (PHASE2)
- Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders (PHASE4)
- Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. (PHASE3)
- A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tocilizumab Prefilled Syringe CI brief — competitive landscape report
- Tocilizumab Prefilled Syringe updates RSS · CI watch RSS
- Syneos Health portfolio CI